Eli Lilly stock rises over 3% as FDA approves once-weekly insulin and new research deal announced

Traders Union
All News
Stocks
Eli lilly rises 3.01% today on fda news

Highlights

The FDA approved Eli Lilly's once-weekly basal insulin Onswik for type 2 diabetes, strengthening its therapeutic portfolio.
Eli Lilly announced annual revenue of $65.18 billion and net profit of $20.64 billion, with ongoing collaborations and acquisitions.
Shares of Eli Lilly are in a long-term bullish trend but immediate technical indicators show potential loss of momentum, with support at $1,180, resistance at $1,197, and a projected five-day range of $1,163 to $1,209.

Product pipeline and dealmaking expand as revenue growth strengthens

The FDA approved Eli Lilly's once-weekly basal insulin, Onswik, for type 2 diabetes, bolstering its product pipeline. The company also entered a research and development collaboration and licensing agreement with InnoCare Pharma to target five unmet medical needs, featuring payments up to $3.25 billion. Additionally, Eli Lilly reported annual revenue of $65.18 billion and net profit of $20.64 billion, and expanded its reach through recent strategic partnerships and acquisitions in the pharmaceuticals sector.

Anton Kharitonov, expert at Traders Union, emphasizes persistent caution despite Eli Lilly’s FDA approval news and share price rally. He highlights technical concerns with bearish MACD and RSI, pointing out uncertainty in short-term momentum. Elevated valuations and divergent oscillator signals suggest the recent surge may be overextended. Kharitonov sees downside risk if support at $1,180 is breached, especially with only a 38% probability for further gains. He warns, "Market optimism is high, but technical exhaustion implies investors should avoid chasing momentum at these levels."

Viktoras Karapetjanc, expert at Traders Union, remains confident about Eli Lilly’s long-term prospects after strong FDA and partnership news. He highlights robust fundamentals, record annual revenue, and a growing product pipeline supporting further growth. Current bullish structure is reinforced by the price holding above all major moving averages. Karapetjanc believes strategic collaborations offer new market opportunities and solidify sector leadership. "Expect the market to reward Lilly’s innovation and partnerships — further upside is likely if resistance at $1,197 is cleared."

Jainam Mehta, market strategist, notes that Eli Lilly’s price action shows strength but diverging oscillators hint at consolidation. He anticipates near-term range-bound trading between $1,163 and $1,209 given mixed momentum signals. For tactical traders, a decisive move above $1,197 could signal a breakout, while a drop below $1,180 would suggest downside. "This divergence in sentiment and price offers latent opportunities for disciplined, scenario-based entries."

Bullish price above averages as divergence emerges in technical signals

Eli Lilly is trading above its 20-day, 50-day, and 200-day moving averages ($1,150, $1,176, and $1,068 respectively), reinforcing bullish short-, medium-, and long-term momentum. Immediate technical levels show resistance at $1,197 and support at $1,180, while the long-term trend remains confirmed bullish. The MACD and Relative Strength Index (RSI) both signal a potential loss of momentum, with the MACD giving a strong sell and the RSI at 46.87 pointing toward a sell. Stochastic RSI is also bearish, and the Commodity Channel Index (CCI) remains neutral. Bull/Bear Power (BBP) is positive at 16.63, indicating that buyers currently dominate intraday momentum, but its overbought signal suggests caution. The session opened with an upside gap of about $33 (2.87%) and is now trading mid-range within the day’s volatility band of 1.58%. Daily movement shows the stock is up $34.62 (3.01%), and intraday tone is showing strength but signals from the oscillators diverge from price action, highlighting some uncertainty in the momentum.

Previously it was reported that Eli Lilly’s FDA approval for Onswik and international expansion had positioned the company for potential upside, though technical indicators reflected some short-term uncertainty. The current analysis adds that while the stock remains above key moving averages, diverging momentum signals warrant close attention to the $1,197 resistance as a pivotal level for potential breakout or consolidation.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.